Core Viewpoint - Masimo Corp. achieved a significant legal victory against Apple Inc. with a $634 million judgment, yet its underlying fundamentals indicate potential weaknesses in operational efficiency and financial health [1][6]. Fundamentals Under Pressure - Masimo's quality score has decreased to 10.43, placing it in the bottom tier of stocks for operational efficiency, indicating underperformance compared to nearly 90% of the market [2][3]. - The company's core operational metrics and historical profitability remain weak relative to industry competitors, despite the cash influx from the lawsuit [3]. Technical Indicators - The stock's momentum score is low at 8.77, reflecting weak relative strength and price movement patterns compared to other stocks [4]. - Masimo's stock is experiencing a downward trend across short, medium, and long timeframes, indicating persistent selling pressure over the past year [5]. Legal Victory - A federal jury in California ruled that Apple infringed on Masimo's blood-oxygen sensor patents, resulting in a $634 million award to Masimo, which the company views as a significant win for its innovation efforts [6]. Stock Performance - In 2025, Masimo's shares dropped by 22.85%, underperforming against the Nasdaq Composite index, which gained 20.54% during the same period [7]. - Over the last six months, the stock fell by 24.09%, closing the last trading day of 2025 at $130.06, with no change in pre-market trading [7].

Masimo Corporation (NASDAQ:MASI) is one of the best NASDAQ stocks to buy in 2026. On December 5, Wells Fargo raised the firm’s price target on Masimo to $190 from $187, while maintaining an Overweight rating on the shares. The firm observed that the company’s Investor Day underscored a strong belief in its sustained, multi-year expansion. Wells Fargo specifically highlighted an expected annual revenue growth rate of 7% to 10% through 2028 and noted that the introduction of new products is projected to push ...

Core Insights - The article highlights significant structural changes in retirement and healthcare financing in the U.S. by 2026, which will impact consumer payment methods for care and competition among medical device companies [1] Policy Changes - The IRS has increased Health Savings Account (HSA) contribution limits for 2026 to $4,400 for individuals and $8,750 for families, up from $4,300 and $8,550 in 2025 respectively [2] - The age-55 "catch-up" contribution remains at $1,000, reflecting cost-of-living adjustments aimed at preserving the tax-advantaged nature of HSAs [3] - Medicare Part B premiums are rising to $202.90 per month, an increase of nearly $18 from 2025, with the Part B deductible increasing to $283 [4] Implications of HSA and Medicare Changes - The rising HSA limits make HSAs more attractive for managing out-of-pocket healthcare costs, while higher Medicare premiums may lead to increased enrollment in Medicare plans and ancillary services [5] - HSAs can be used for both current medical costs and qualified medical device expenses, allowing consumers to save more tax-free dollars for durable medical equipment [6] - Higher premiums may increase demand for technologies that improve disease self-management and prevent costly complications, influencing total care costs [7] Companies Positioned to Benefit - DexCom, ResMed, and Masimo are identified as companies likely to benefit from these trends due to their focus on markets where out-of-pocket costs and reimbursement policies significantly affect adoption [8] - DexCom's continuous glucose monitoring (CGM) systems may see increased adoption as higher HSA limits help patients manage diabetes costs [9] - ResMed's devices for sleep and respiratory care align with the aging Medicare demographic and rising out-of-pocket care needs [9] - Masimo's monitoring tools support preventive care, which becomes more relevant as Medicare premiums rise [9] Company-Specific Insights - DexCom is a leader in CGM systems, providing real-time glucose data that aids in insulin delivery and lifestyle management, with a focus on expanding Medicare coverage for CGM devices [10][11] - Higher HSA limits allow diabetes patients to allocate more pre-tax savings for CGM systems, reducing financial barriers to adoption [12] - ResMed specializes in devices for sleep-disordered breathing, with rising premiums incentivizing seniors to use HSAs for optimal therapy devices [15][16] - Masimo develops non-invasive monitoring systems, with increased demand for preventive monitoring as Medicare beneficiaries face higher premiums [18][19]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zack ...

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Masimo Corporation, which may affect shareholder rights and corporate governance [1][2]. Group 1: Legal Investigation - The law firm is looking into whether Masimo Corporation's management has acted against the interests of shareholders [1]. - Long-term shareholders may have options for seeking corporate governance reforms and financial recovery [2]. Group 2: Shareholder Involvement - Shareholder participation is emphasized as a means to improve company policies and enhance overall shareholder value [3]. Group 3: Firm's Background - Halper Sadeh LLC has a history of representing investors affected by securities fraud and corporate misconduct, successfully recovering millions for defrauded investors [4].

Core Insights - Masimo Corp hosted its 2025 Investor Day, outlining its long-term strategy and growth pillars, projecting a revenue CAGR of 7%–10% through 2028 and operating margins of about 30% [1][2] - The company aims for adjusted EPS of $8.00 by 2028 and expects to generate approximately $1 billion in cumulative operating cash flow from 2026 to 2028 [2] - Masimo reaffirmed its 2025 financial guidance, projecting revenue between $1.51 billion and $1.53 billion, operating profit between $412 million and $424 million, and EPS between $5.40 and $5.55 [2][5] Financial Performance - In the third quarter, Masimo reported adjusted earnings of $1.32 per share, exceeding the consensus of $1.20, with sales of $371.2 million, surpassing the consensus of $366.85 million [5] - The company raised its fiscal 2025 adjusted earnings forecast from $5.45-$5.70 per share to $5.62-$5.79, compared to the consensus of $5.33 [5] - Masimo narrowed its fiscal 2025 sales outlook from $1.51 billion-$1.54 billion to $1.51 billion-$1.53 billion, aligning with the consensus of $1.52 billion [5] Market Position and Analyst Sentiment - Masimo's CEO emphasized the company's mission to deliver innovations that empower clinicians and transform patient care, indicating a strong market position [3] - Analyst ratings from BTIG maintain a Buy rating for Masimo, raising the price forecast from $198 to $200 [3] Legal Developments - A federal jury ruled that Apple must pay Masimo $634 million for infringing a patent related to blood-oxygen reading technology, marking a significant legal victory for the company [4]

Core Insights - Masimo is hosting its 2025 Investor Day to present its strategic vision and operational updates to investors [1][2] - The agenda includes presentations from the executive team focusing on Masimo's strong foundation and plans for expanding its leadership in advanced monitoring [4] Company Overview - Masimo has recently appointed Matthew Brinckman as Senior Vice President of FP&A and Investor Relations, indicating a focus on enhancing investor communication [1] - The company emphasizes the use of non-GAAP measures in its presentations to provide a clearer understanding of its business performance [3]

Summary of Masimo's 2025 Investor Day Company Overview - **Company**: Masimo - **Industry**: Advanced patient monitoring technology - **Key Focus**: Transforming patient care through innovative monitoring solutions, particularly in pulse oximetry and advanced monitoring systems [11][12][13] Core Points and Arguments 1. **Market Leadership**: Masimo is the global leader in patient monitoring, with a significant market share in pediatric and neonatal intensive care environments, attributed to its advanced algorithms for pulse oximetry [9][12] 2. **Patient Impact**: The company aims to make a difference in the lives of over 200 million patients annually across 150 countries [11] 3. **Financial Targets**: Masimo has set long-term financial targets for 2028, aiming for 7%-10% growth, with aspirations for double-digit growth beyond that [17][33] 4. **Product Pipeline**: The company has a multi-year product pipeline, including new algorithms for detecting atrial fibrillation and opioid-induced respiratory depression, expected to launch in 2026 [29][43] 5. **Recurring Revenue**: Masimo boasts an 80% recurring revenue model, supported by a large installed base of over 2.6 million units and a 98% renewal rate on long-term contracts [12][17] 6. **International Expansion**: There is a significant opportunity for growth in international markets, where Masimo currently holds a lower market share compared to the U.S. [24][46] 7. **Clinical Evidence**: The company emphasizes the importance of clinical evidence to validate its technologies, with ongoing studies demonstrating the accuracy of its sensors across different skin tones [60][62] Additional Important Content 1. **Leadership Team**: The leadership team combines long-standing Masimo employees with new talent from other top med tech companies, enhancing the company's innovation and execution capabilities [18][20] 2. **Restructuring and Focus**: The company has undergone restructuring to focus on its core healthcare business, divesting non-core assets like Sound United [13][14] 3. **Intellectual Property**: Masimo is actively defending its intellectual property, recently winning a significant verdict in a case against Apple, which underscores the company's commitment to protecting its innovations [32][33] 4. **Patient Monitoring Opportunities**: The company identifies a $2 billion market opportunity in surveillance monitoring, highlighting the potential for continuous monitoring to prevent costly ICU re-admissions [28][46] 5. **Commercial Strategy**: The commercial team is focused on leveraging the installed base and enhancing sales strategies to drive growth, with a nearly 100% retention rate over the past decade [40][41] This summary encapsulates the key insights and strategic directions discussed during Masimo's 2025 Investor Day, emphasizing the company's commitment to innovation, patient care, and market expansion.

Financial Performance & Targets - Masimo's FY2025E total revenue is projected to be over $1.5 billion[11] - The company anticipates revenue growth of 9% in 2025E, which includes the impact of a 53rd week in the fiscal year[15] - Masimo expects Non-GAAP EPS growth of 67% in 2025E, reaching $5.62-$5.79[15] - The company targets a revenue CAGR of 7%-10% through 2028[21] - Masimo aims to achieve an operating margin of approximately 30% by 2028[21] - The company projects adjusted EPS of $8.00 by 2028[21] - Masimo forecasts cumulative operating cash flow of around $1 billion from 2026 to 2028[21] Market & Growth Strategy - Masimo estimates that over 200 million patients are monitored each year using Masimo SET® technology in over 150 countries[11] - The company has an installed base of approximately 2.6 million technology boards and monitors[11] - Masimo aims to increase its US Pulse Oximetry market share from ~55% to 58%-60% by 2028[32, 80] - The international Pulse Oximetry market represents a ~$800 million market with 6%-8% annual growth[32]